Proposed Data Collections Submitted for Public Comment and Recommendations, 47640-47641 [2014-19245]
Download as PDF
47640
Federal Register / Vol. 79, No. 157 / Thursday, August 14, 2014 / Notices
Open to the Public
terminal at the Port of Tacoma. The
Parties request expedited review.
1. Approval of the Minutes of the July
28, 2014 Board Member Meeting
2. Monthly Reports
a. Monthly Participant Activity Report
b. Quarterly Investment Report
c. Legislative Report
3. Quarterly Metrics Reports
4. Office of Enterprise Risk Management
(OERM) Report
5. FY 15 Budget Review and Approval
CONTACT PERSON FOR MORE INFORMATION:
Kimberly Weaver, Director, Office of
External Affairs, (202) 942–1640.
By Order of the Federal Maritime
Commission.
Dated: August 8, 2014.
Karen V. Gregory,
Secretary.
[FR Doc. 2014–19183 Filed 8–13–14; 8:45 am]
BILLING CODE 6730–01–P
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
notices are set forth in paragraph 7 of
the Act (12 U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the offices of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than August
27, 2014.
A. Federal Reserve Bank of Atlanta
(Chapelle Davis, Assistant Vice
President) 1000 Peachtree Street NE.,
Atlanta, Georgia 30309:
1. Andrew Litsch and Joshua Litsch,
both of Edmond, Oklahoma, to acquire
control of First of Grandfield
Corporation, parent of First State Bank,
both in Grandfield, Oklahoma.
Board of Governors of the Federal Reserve
System, August 11, 2014.
Michael J. Lewandowski,
Assistant Secretary of the Board.
[FR Doc. 2014–19258 Filed 8–13–14; 8:45 am]
BILLING CODE 6210–01–P
FEDERAL RETIREMENT THRIFT
INVESTMENT BOARD
tkelley on DSK3SPTVN1PROD with NOTICES
Sunshine Act Meeting
8:30 a.m. (Eastern Time)
August 21, 2014.
PLACE: 10th Floor Board Meeting, Room
77 K Street NE., Washington, DC 20002.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
TIME AND DATE:
VerDate Mar<15>2010
16:42 Aug 13, 2014
Jkt 232001
Dated: August 12, 2014.
James Petrick,
General Counsel, Federal Retirement Thrift
Investment Board.
[FR Doc. 2014–19379 Filed 8–12–14; 4:15 pm]
BILLING CODE 6760–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day-14–14ARR]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
The Centers for Disease Control and
Prevention (CDC), as part of its
continuing effort to reduce public
burden, invites the general public and
other Federal agencies to take this
opportunity to comment on proposed
and/or continuing information
collections, as required by the
Paperwork Reduction Act of 1995. To
request more information on the below
proposed project or to obtain a copy of
the information collection plan and
instruments, call 404–639–7570 or send
comments to Leroy Richardson, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments submitted in response to
this notice will be summarized and/or
included in the request for Office of
Management and Budget (OMB)
approval. Comments are invited on: (a)
Whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; (d) ways to
minimize the burden of the collection of
information on respondents, including
through the use of automated collection
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
techniques or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. Written comments should
be received within 60 days of this
notice.
Proposed Project
Drug Overdose Response Investigation
(DORI) Data Collections—New—
National Center for Injury Prevention
and Control (NCIPC), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
State and local health authorities
frequently call upon CDC’s National
Center for Injury Prevention and Control
(NCIPC) to assist in their response to
urgent public health problems resulting
from drug use, misuse, abuse, and
overdose. When called, NCIPC supports
the states and local health authorities by
conducting Drug Overdose Response
Investigations (DORI), which entails a
rapid and flexible epidemiological
response. Urgent requests such as DORIs
depend on the time and resources
available, number of persons involved,
and other circumstances unique to the
urgent conditions at hand and usually
involve the development of procedures,
specific data collection instruments, and
the collection of critical data.
This request is for a new generic
approval to conduct information
collections during DORIs. A three-year
clearance is requested to ensure: (1)
Rapid deployment data collection tools
and (2) timely information collection of
vital information. Of particular interest
is response to increasing trends in, or
changing characteristics of, overdose
from prescription drugs (with a special
interest in opioid analgesics such as
oxycodone or methadone;
benzodiazepines such as alprazolam)
and/or illicit drugs (e.g., heroin).
Specifically, this request covers
investigative collections with the
E:\FR\FM\14AUN1.SGM
14AUN1
47641
Federal Register / Vol. 79, No. 157 / Thursday, August 14, 2014 / Notices
following aims: (1) To understand
sudden increases in drug use and
misuse associated with fatal and
nonfatal overdoses; (2) to understand
the drivers and risk factors associated
with those trends; and (3) to identify the
groups most affected. This will allow
CDC to effectively advise states on
recommended actions to control local
epidemics. Thus, the ultimate goals of
these collections are to minimize
adverse health consequences, provide
epidemiological data collection support
to the states and, based on the findings
from the investigation, appropriately
assist with implementation of
prevention and control measures.
Data are collected by epidemiologists,
psychologists, medical professionals,
subject matter experts, and
biostatisticians. Examples of data
collection modes that may be employed
during DORIs include: Archival record
abstractions and reviews, face-to-face
interviews, telephone interviews, webbased questionnaires, and selfadministered questionnaires.
For example, information collected
through archival chart review from
history, co-occurring health conditions
(e.g., abnormal snoring indicative of
respiratory depression), mental health
conditions (e.g., depression, anxiety
disorders), enrollment in drug treatment
program, sources of drugs, route of drug
administration, criminal history, and so
forth. Finally, collection of spatial
information could be obtained through
city, county, and state government
agencies to determine structural and
environmental factors associated with
location of overdose deaths.
Respondent type will also vary by
investigation, but will include
organizations typically involved in
prevention, intervention, and response
to drug overdose (e.g., public health,
law enforcement authorities, health
systems, and community organizations.
Respondents also may include victims
of non-fatal drug overdoses, as well as
family and friends of victims.
During a DORI, data are collected
once, with the rare need for follow-up.
There are no costs to respondents other
than their time.
hospitals and medical examiners could
include demographics, drug use history,
reported medical and mental health
conditions, place of overdose, place of
death, drug paraphernalia on the scene,
mode of administration, observers
present, naloxone administration,
hospital admittance, autopsy findings,
toxicology results, and so forth.
Information collected through
interviews with representatives from
agencies involved in preventing,
intervening, or responding to drug
overdose could include professional
history, personal experience with drug
overdose cases or investigations,
prevention or intervention efforts
engaged in, perceptions of
characteristics of or changes in drug
overdose cases (e.g., transition from
opioids to heroin; increasing or
decreasing rates), and so forth.
Collection of information from nonfatal
overdose victims, and friends and
family of overdose victims could
include substance use history,
prescription drug history, number of
providers and pharmacies used, pain
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses
per
respondent
Number of
respondents
Average
burden per
response
(in hours)
Total
burden
hours
Type of respondent
Form name
Drug Overdose Response Investigation Participants.
Drug Overdose Response Investigation Data Collection Instruments.
2,700
1
.5
1,350
Total ...........................................
..........................................................
........................
........................
........................
1,350
Leroy Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2014–19245 Filed 8–13–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
tkelley on DSK3SPTVN1PROD with NOTICES
Advisory Committee on Breast Cancer
in Young Women (ACBCYW)
Correction
The notice for this August 11, 2014
meeting was published in the Federal
Register on July 15, 2014, Volume 79,
Number 135, Page 41289. Due to
unforeseen technological issues, the
previously published Web access has
been changed. This change occurred too
VerDate Mar<15>2010
16:42 Aug 13, 2014
Jkt 232001
close to the meeting date for CDC to be
able to provide advance notification to
the public. The revised web access
information and link were posted on the
committee Web site in advance of the
meeting; and the information was
announced during the meeting for
members of the public who joined the
meeting by phone.
For additional information on
ACBCYW please visit the ACBCYW site:
https://www.cdc.gov/cancer/breast/
what_cdc_is_doing/young_women.htm
Contact Person for More Information:
Temeika L. Fairley, Ph.D., Designated
Federal Officer, National Center for
Chronic Disease Prevention and Health
Promotion, CDC, 5770 Buford Highway,
NE., Mailstop F76, Atlanta, Georgia
30341, Telephone (770) 488–4518, Fax
(770) 488–4760, Email: acbcyw@cdc.gov
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
PO 00000
Frm 00030
Fmt 4703
Sfmt 9990
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Gary J. Johnson,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2014–19202 Filed 8–13–14; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\14AUN1.SGM
14AUN1
Agencies
[Federal Register Volume 79, Number 157 (Thursday, August 14, 2014)]
[Notices]
[Pages 47640-47641]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-19245]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-14-14ARR]
Proposed Data Collections Submitted for Public Comment and
Recommendations
The Centers for Disease Control and Prevention (CDC), as part of
its continuing effort to reduce public burden, invites the general
public and other Federal agencies to take this opportunity to comment
on proposed and/or continuing information collections, as required by
the Paperwork Reduction Act of 1995. To request more information on the
below proposed project or to obtain a copy of the information
collection plan and instruments, call 404-639-7570 or send comments to
Leroy Richardson, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send
an email to omb@cdc.gov.
Comments submitted in response to this notice will be summarized
and/or included in the request for Office of Management and Budget
(OMB) approval. Comments are invited on: (a) Whether the proposed
collection of information is necessary for the proper performance of
the functions of the agency, including whether the information shall
have practical utility; (b) the accuracy of the agency's estimate of
the burden of the proposed collection of information; (c) ways to
enhance the quality, utility, and clarity of the information to be
collected; (d) ways to minimize the burden of the collection of
information on respondents, including through the use of automated
collection techniques or other forms of information technology; and (e)
estimates of capital or start-up costs and costs of operation,
maintenance, and purchase of services to provide information. Burden
means the total time, effort, or financial resources expended by
persons to generate, maintain, retain, disclose or provide information
to or for a Federal agency. This includes the time needed to review
instructions; to develop, acquire, install and utilize technology and
systems for the purpose of collecting, validating and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
a collection of information, to search data sources, to complete and
review the collection of information; and to transmit or otherwise
disclose the information. Written comments should be received within 60
days of this notice.
Proposed Project
Drug Overdose Response Investigation (DORI) Data Collections--New--
National Center for Injury Prevention and Control (NCIPC), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
State and local health authorities frequently call upon CDC's
National Center for Injury Prevention and Control (NCIPC) to assist in
their response to urgent public health problems resulting from drug
use, misuse, abuse, and overdose. When called, NCIPC supports the
states and local health authorities by conducting Drug Overdose
Response Investigations (DORI), which entails a rapid and flexible
epidemiological response. Urgent requests such as DORIs depend on the
time and resources available, number of persons involved, and other
circumstances unique to the urgent conditions at hand and usually
involve the development of procedures, specific data collection
instruments, and the collection of critical data.
This request is for a new generic approval to conduct information
collections during DORIs. A three-year clearance is requested to
ensure: (1) Rapid deployment data collection tools and (2) timely
information collection of vital information. Of particular interest is
response to increasing trends in, or changing characteristics of,
overdose from prescription drugs (with a special interest in opioid
analgesics such as oxycodone or methadone; benzodiazepines such as
alprazolam) and/or illicit drugs (e.g., heroin).
Specifically, this request covers investigative collections with
the
[[Page 47641]]
following aims: (1) To understand sudden increases in drug use and
misuse associated with fatal and nonfatal overdoses; (2) to understand
the drivers and risk factors associated with those trends; and (3) to
identify the groups most affected. This will allow CDC to effectively
advise states on recommended actions to control local epidemics. Thus,
the ultimate goals of these collections are to minimize adverse health
consequences, provide epidemiological data collection support to the
states and, based on the findings from the investigation, appropriately
assist with implementation of prevention and control measures.
Data are collected by epidemiologists, psychologists, medical
professionals, subject matter experts, and biostatisticians. Examples
of data collection modes that may be employed during DORIs include:
Archival record abstractions and reviews, face-to-face interviews,
telephone interviews, web-based questionnaires, and self-administered
questionnaires.
For example, information collected through archival chart review
from hospitals and medical examiners could include demographics, drug
use history, reported medical and mental health conditions, place of
overdose, place of death, drug paraphernalia on the scene, mode of
administration, observers present, naloxone administration, hospital
admittance, autopsy findings, toxicology results, and so forth.
Information collected through interviews with representatives from
agencies involved in preventing, intervening, or responding to drug
overdose could include professional history, personal experience with
drug overdose cases or investigations, prevention or intervention
efforts engaged in, perceptions of characteristics of or changes in
drug overdose cases (e.g., transition from opioids to heroin;
increasing or decreasing rates), and so forth. Collection of
information from nonfatal overdose victims, and friends and family of
overdose victims could include substance use history, prescription drug
history, number of providers and pharmacies used, pain history, co-
occurring health conditions (e.g., abnormal snoring indicative of
respiratory depression), mental health conditions (e.g., depression,
anxiety disorders), enrollment in drug treatment program, sources of
drugs, route of drug administration, criminal history, and so forth.
Finally, collection of spatial information could be obtained through
city, county, and state government agencies to determine structural and
environmental factors associated with location of overdose deaths.
Respondent type will also vary by investigation, but will include
organizations typically involved in prevention, intervention, and
response to drug overdose (e.g., public health, law enforcement
authorities, health systems, and community organizations. Respondents
also may include victims of non-fatal drug overdoses, as well as family
and friends of victims.
During a DORI, data are collected once, with the rare need for
follow-up. There are no costs to respondents other than their time.
Estimated Annualized Burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondent Form name respondents responses per response (in hours
respondent hours)
--------------------------------------------------------------------------------------------------------------------------------------------------------
Drug Overdose Response Investigation Drug Overdose Response Investigation 2,700 1 .5 1,350
Participants. Data Collection Instruments.
---------------------------------------------------------------
Total...................................... ....................................... .............. .............. .............. 1,350
--------------------------------------------------------------------------------------------------------------------------------------------------------
Leroy Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2014-19245 Filed 8-13-14; 8:45 am]
BILLING CODE 4163-18-P